Cormedix Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 191

Employees

  • Stock Symbol
  • CRMD

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $5.27
  • (As of Friday Closing)

Cormedix General Information

Description

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Contact Information

Formerly Known As
Picton Holding Company
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 389 Interpace Parkway
  • Suite 450
  • Parsippany, NJ 07054
  • United States
+1 (908)
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 389 Interpace Parkway
  • Suite 450
  • Parsippany, NJ 07054
  • United States
+1 (908)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cormedix Stock Performance

As of 20-Nov-2026, Cormedix’s stock price is $5.27. Its current market cap is $419M with 79.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.27 $5.08 $4.46 - $13.02 $419M 79.5M 1.44M $0.81

Cormedix Financials Summary

As of 30-Sep-2026, Cormedix has a trailing 12-month revenue of $404M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 488,629 1,009,521 446,012 120,209
Revenue 404,184 311,709 43,472 0
EBITDA 176,423 163,501 (21,558) (48,916)
Net Income 63,887 163,055 (17,930) (46,339)
Total Assets 917,745 826,142 118,846 82,060
Total Debt 145,421 148,914 517 668
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cormedix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cormedix‘s full profile, request access.

Request a free trial

Cormedix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre
Pharmaceuticals
Parsippany, NJ
191 As of 2026

Denver, CO
 

Bridgewater, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cormedix Competitors (29)

One of Cormedix’s 29 competitors is Aytu Biopharma, a Formerly VC-backed company based in Denver, CO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aytu Biopharma Formerly VC-backed Denver, CO
Amneal Pharmaceuticals Formerly PE-Backed Bridgewater, NJ
Novartis Corporation Basel, Switzerland
Evonile Pharma Private Equity-Backed Mumbai, India
China Resources Pharmaceutical Group Corporation Hong Kong, Hong Kong
You’re viewing 5 of 29 competitors. Get the full list »

Cormedix Patents

Cormedix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4507746-A1 Improved synthesis of taurolidine, purity profiles and polymorphs Pending 14-Apr-2022
EP-4507746-A4 Improved synthesis of taurolidine, purity profiles and polymorphs Pending 14-Apr-2022
US-20250249153-A1 Improved synthesis of taurolidine, purity profiles and polymorphs Pending 14-Apr-2022
WO-2023201019-A1 Improved synthesis of taurolidine, purity profiles and polymorphs Inactive 14-Apr-2022
US-11738120-B1 Synthesis of taurolidine, purity profiles and polymorphs Active 14-Apr-2022 A61K31/549
To view Cormedix’s complete patent history, request access »

Cormedix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cormedix Investments & Acquisitions (3)

Cormedix’s most recent deal was a Merger/Acquisition with Heron Therapeutics for . The deal was made on 09-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Heron Therapeutics 09-Nov-2026 Merger/Acquisition Drug Discovery
Talphera 10-Sep-2025 PIPE Drug Discovery
Melinta Therapeutics 29-Aug-2025 Merger/Acquisition Pharmaceuticals
To view Cormedix’s complete investments and acquisitions history, request access »

Cormedix ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.35 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Cormedix’s complete esg history, request access »

Cormedix FAQs

  • When was Cormedix founded?

    Cormedix was founded in 2006.

  • Where is Cormedix headquartered?

    Cormedix is headquartered in Parsippany, NJ.

  • What is the size of Cormedix?

    Cormedix has 191 total employees.

  • What industry is Cormedix in?

    Cormedix’s primary industry is Pharmaceuticals.

  • Is Cormedix a private or public company?

    Cormedix is a Public company.

  • What is Cormedix’s stock symbol?

    The ticker symbol for Cormedix is CRMD.

  • What is the current stock price of Cormedix?

    As of 20-Nov-2026 the stock price of Cormedix is $5.27.

  • What is the current market cap of Cormedix?

    The current market capitalization of Cormedix is $419M.

  • What is Cormedix’s current revenue?

    The trailing twelve month revenue for Cormedix is $404M.

  • Who are Cormedix’s competitors?

    Aytu Biopharma, Amneal Pharmaceuticals, Novartis, Evonile Pharma, and China Resources Pharmaceutical Group are some of the 29 competitors of Cormedix.

  • What is Cormedix’s annual earnings per share (EPS)?

    Cormedix’s EPS for 12 months was $0.81.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process